Sun Pharma posts net profit of Rs 1,391 crore

BS Reporter Mumbai
Last Updated : Aug 13 2014 | 1:43 AM IST
Sun Pharmaceuticals, India's largest drug maker by market value, has posted a net profit of Rs 1,391 crore in the first quarter of FY15, compared with a net loss of Rs 1,276 in the year-ago period. Net sales for the June 2014 quarter stood at Rs 3,927 crore, a growth of 13 per cent over same quarter last year. The loss in the June 2013 quarter was on account of a provision of Rs 2,517 crore towards settlement for patent infringement litigation related to generic versions of 'Protonix', the company said in a statement.

The performance was pushed by the better sale of branded prescription formulations in India at Rs 992 crore, up 17 per cent from the first quarter of FY14.

Sun Pharma is ranked second in India and holds a 5.4 per cent market share in the Rs 77,000-crore pharma market. On Tuesday, Sun Pharma shares were closed at Rs 783.9 apiece.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 13 2014 | 12:16 AM IST

Next Story